Stay up to date on PsychoGenics and the world of preclinical drug discovery. Press Releases Press ReleasesPsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare DisordersAugust 28, 2024 Press ReleasesUnlock New Possibilities with PsychoGenics’ Special Offer!January 24, 2024 Press ReleasesPsychoGenics Achieves Top Supplier Status on Scientist.com for 2023December 22, 2023 Press ReleasesPsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric DisordersDecember 1, 2023 Press ReleasesPsychoGenics Launches Updated Corporate Identity and BrandNovember 10, 2023 Press ReleasesPsychoGenics and Collaborations Pharmaceuticals Awarded a $1M grant to Use AI Platforms to Design New Drugs for Mental Health DisordersSeptember 5, 2023 Press ReleasesPsychoGenics Highlights a Long-term Collaboration with the TSC Alliance on Rare Disease DayFebruary 28, 2023 Press ReleasesPsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna TherapeuticsOctober 11, 2022 Press ReleasesPsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO CapabilitiesJune 29, 2022 Press ReleasesPsychoGenics’ High Data Security Standards Are Certified by The NIHJanuary 25, 2022 Industry News Industry NewsBack to the future: From target-selective drug design to AI-enabled polypharmacologyMay 20, 2024 Industry NewsThe Christopher and Dana Reeve Foundation Announces #3.1M Spinal Cord Injury Research GrantsMarch 6, 2024 Industry NewsThis company is using AI to develop drugs. Schizophrenia is its first targetAugust 4, 2023 Industry NewsWorld Wellbeing Week 2023: Celebrating drug discovery innovationJune 29, 2023 Industry NewsHow AI Will Make Our Lives Better (And Worse)May 31, 2023 Industry NewsAI-Discovered Drug Shows ‘Enormous Potential’ to Treat Schizophrenia: ‘Real Need for Better Treatment’May 10, 2023 Industry NewsPsychoGenics’ SmartCube Prompts a Reevaluation of CNS Drug DiscoveryMay 8, 2023 Industry NewsPsychoGenics Launches eCube AI Platform for Drug DiscoveryApril 11, 2023 Industry NewsPsychoGenics Introduces eCube, an AI-Driven Platform for Drug Discovery in Neuropsychiatric DisordersApril 11, 2023 Industry NewsPsychoGenics Launches AI Platform to Revolutionize Drug DiscoveryApril 6, 2023